News

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...
Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...
U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...
Lilly’s shares were impacted after a difficult month for its weight loss drug, A recent study showed the pill form of Lilly's ...
A restful night’s sleep is vital to a healthy lifestyle but an Indiana physician said most Americans are not getting enough ...
The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...
By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...
An Anthem Blue Cross subscriber is suing the health insurer, alleging she was wrongfully denied coverage for Zepbound for weight management because she was no longer considered morbidly obese. Alicia ...
The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...
Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.
Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...